Department of Medicine 5 – Haematology and Oncology

HLA-DO: a possible switch between GvHD and GvL effect (2022) Zeun J, Neubeck S, Lang V, Flamann C, Nagel L, Kunert T, Vogler T, et al. Conference contribution Microbiota-derived propionate modulates megakaryopoiesis and platelet function (2022) Schmid E, Dürholz K, Frech M, Otterbein N, Lucas S, Rauh M, Schett G, et al. Conference contribution CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus (2022) Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, et al. Conference contribution BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours (2022) Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, Borchmann P, et al. Conference contribution Prophylaxis of bacterial Infections and Pneumocystis jirovecii pneumonia in Female Patients with hematological and oncological Diseases: Updated Guideline of the Working Group on Infections (AGIHO) of the German Society for Hematology and Oncology (DGHO) (2022) Classen AY, Henze L, Von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Duran GL, Alakel N, et al. Conference contribution Immune Checkpoint Co-blockade of CD47 and HLA Class I Receptors to increase CD20 Antibody-mediated Phagocytosis of Lymphoma Cells (2022) Zeller T, Lutz S, Munnich IA, Windisch R, Hilger P, Herold T, Tahiri N, et al. Conference contribution Recording of the regional Origin Areas of Patients from the Molecular Tumor Board to Identify the "white Spots" in the Service Area - A joint Initiative of the Bavarian CCC WERA Alliance (2022) Lueke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spörl S, et al. Conference contribution The CAR-HAMATOTOX for risk stratification of severe infections and for the adjustment of antibacterial prophylaxis prior to CD19-targeted CAR T-cell therapy (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Buecklein , Mougiakakos D, Blumenberg , et al. Conference contribution Reproducibility of measurable residual disease detection by flow cytometry in acute myeloid leukemia (2022) Roehnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause S, Buecklein V, et al. Conference contribution Early Expansion of CD19.CAR-T Cells in vivo identify the Patients at Risk for the Treatment Failure in diffuse large B-Cell Lymphoma (2022) Blumenberg V, Busch G, Baumann S, Jitschin R, Winkelmann M, Hellwig K, Schmidt C, et al. Conference contribution